[CLSTR]
< Back to situation

[REVISION HISTORY]

Advances in cancer immunotherapy and resistance strategies

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-08-26 02:13 UTC → 2026-08-26 15:59 UTC · added removed

Cancer Advances in cancer immunotherapy research and resistance strategies

Academic research has focused on advancing continues to advance immunotherapeutic approaches to treat for aggressive cancer types, including cancers, such as HPV-driven head and neck squamous cell carcinoma (HNSCC) and triple-negative breast cancer (TNBC). Early studies examined efforts focused on using immune checkpoint inhibitors like ipilimumab and nivolumab to enhance T cell and natural killer (NK) cell functions by blocking inhibitory signaling pathways. For TNBC, researchers investigated targeting cancer stem cells through flavonoid supplements or combining chemotherapy with inhibitors to overcome resistance to anti-PD-L1 therapies. Subsequent functions. Recent developments have targeted the mechanisms of immunotherapy expanded into sophisticated engineering and timing strategies to overcome resistance in solid tumors. At The University of Texas at Austin, scientists identified that the protein EREG allows dormant pancreatic cancer cells to suppress CAR T-cell activity via macrophages; blocking this protein significantly extended survival in mouse models. At Cornell University, researchers demonstrated that activating macrophages after targeted drug treatments can eliminate residual melanoma cells. Additionally, Stanford Medicine Medicine, researchers have successfully reprogrammed circulating NK cells into tissue-resident cells using TGF-b, enabling specific levels of TGF-b signaling, allowing them to penetrate dense tumor microenvironments to attack melanoma and slow HNSCC. At UC San Francisco, scientists have engineered a technique using induced pluripotent stem cells (iPSCs) to create dendritic cells. These cells are “dressed” with membrane bubbles from a patient’s own tumor to train T cells to identify and eradicate specific malignancies, including leukemia and ovarian cancer. Further research at Cornell University emphasizes the growth importance of therapeutic timing; by using a compound to activate macrophages after targeted drugs induce resistance, researchers were able to eliminate more residual melanoma and HNSCC cells in preclinical mouse models. Additionally, the development of a new microfluidic platform called ATTACH provides an unbiased method for isolating antigen-specific T cells, leveraging tumor cells to enrich rare tumor-reactive T-cell populations by up to 10-fold.

Versions

  1. 2026-08-26 15:59 UTC Advances in cancer immunotherapy and resistance strategies
  2. 2026-08-26 02:13 UTC Cancer immunotherapy research and resistance strategies

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.